Infliximab-associated bilateral nonarteritic ischemic optic neuropathy in chronic plaque psoriasis treatment.

Authors

Jenna Currier
Tina Abraham, Corewell Health East
George J Murakawa

Document Type

Article

Publication Date

3-30-2025

Publication Title

JAAD case reports

Abstract

Tumor necrosis factor-alpha (TNF-alpha) is a key inflammatory mediator involved in the pathogenesis of many chronic immunologic conditions, including chronic plaque psoriasis.¹ To target TNF-alpha in psoriasis treatment, several drugs have been developed, such as infliximab, adalimumab, and etanercept.¹

Infliximab has been approved by the Food and Drug Administration for dermatologic use since 2005 for the treatment of psoriatic arthritis, followed by approval for chronic plaque psoriasis in 2006.^2,3 Aside from its dermatologic applications, infliximab has been approved for the treatment of Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis.⁴ While it is generally considered safe, side effects include headache, rash, myalgia, hepatotoxicity, and in rare cases, optic neuropathy.⁴ To date, only 4 cases of anterior ischemic optic neuropathy have been reported with infliximab use, all involving non-dermatologic conditions like rheumatoid arthritis and Crohn’s esophagitis.^5,6 Herein, we report the first case of bilateral nonarteritic anterior ischemic optic neuropathy (NAION) following infliximab treatment for chronic plaque psoriasis.

Volume

60

First Page

83

Last Page

85

Recommended Citation

Currier J, Abraham T, Murakawa GJ. Infliximab-associated bilateral nonarteritic ischemic optic neuropathy in chronic plaque psoriasis treatment. JAAD Case Rep. 2025 Mar 30;60:83-85. doi: 10.1016/j.jdcr.2025.03.011. PMID: 40353111

DOI

10.1016/j.jdcr.2025.03.011

ISSN

2352-5126

PubMed ID

40353111